Visiongain has published a new report entitled Preparation of viral vectors and plasmid DNA 2022-2032. It profiles the Viral Vectors and Plasmid DNA Manufacturing market segment and forecasts by vector type (adenovirus, retrovirus, plasmid DNA, AAV, lentivirus, others), market segment by application (antisense & RNAi, gene therapy, cell therapy, vaccinology), market segment by end-use (pharmaceutical and biopharmaceutical companies, research institutes). ), Market Segment by Disease (Oncology, Genetic Disorders, Infectious Diseases, Other), Market Segment by Workflow (Upstream, Downstream), plus COVID-19 Impact Analysis and Recovery Pattern Analysis (“V” shaped, “W” shaped, “U” shaped, “L” shaped), profiles of leading companies, region and country.
The viral vector and plasmid DNA manufacturing market was valued at US$482.3 million in 2021 and is projected to grow at a CAGR of 18.09% during the forecast period 2022-2032.
Challenges related to the lack of viral vector production capacity
Due to the proliferation of clinical-stage start-ups, contract manufacturers that new gene and cell therapy companies rely on for early-stage development activities are suffering from a lack of viral vector manufacturing capacity. To avoid the challenges of outsourcing, when these companies reach commercial scale, they typically choose to retain complete control of their manufacturing. As a result, biotech companies began preparing for growth, organizing internal teams and/or seeking advice from site consultants. These experts help in the search for suitable R&D facilities or, increasingly, new construction sites in the markets.
These in-house capabilities enable gene and cell therapy companies to quickly scale production from clinical to commercial scale, even when therapies are still in the R&D phase. This also allows for co-location with R&D operations, allowing for smooth technology transfer with minimal disruption. Existing buildings that are becoming increasingly difficult to…
